Private health care market in Central Europe looks to gather momentum by 2018

21 July 2014

New data from Poland-based research company PRM is forecasting a revival of the private healthcare market in Central Europe between 2014 and 2018.

The report “Private healthcare market in Central Europe in 2014. Development forecasts for 2014-2018” shows that the market in Central Europe (Poland, Romania, Bulgaria, Hungary, the Czech Republic and Slovakia) was worth 6.1 billion euros in 2013 ($8.2 billion), though market growth fell slightly short of that in 2012 due to a deterioration in macroeconomic conditions. The shares of individual countries as a proportion of the private health care market value in Central Europe shows Poland and the Czech Republic to be the biggest contributors in the region in both 2009 and 2013. Across the same period, Slovakia and Hungary both reduced their market share in the wake of unfavorable reforms.

Recession had ongoing effect in Central Europe

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK